Iloprost modulates the immune response in systemic sclerosis

被引：0
|
作者：
Patrizia D'Amelio
Maria A Cristofaro
Lucia D'Amico
Luciana Veneziano
Ilaria Roato
Francesca Sassi
Giuseppina Bisignano
Marta Saracco
Raffaele Pellerito
Salvatore Patanè
Riccardo Ferracini
Gian P Pescarmona
Giovanni C Isaia
机构：
[1] University of Torino,Gerontology Section, Department of Surgical and Medical Disciplines
[2] A.O.U. San Giovanni Battista,CeRMS (Center for Research and Medical Studies)
[3] Division of rheumatology "Ordine Mauriziano" Hospital,Department of Orthopaedics
[4] A.O.U. San Giovanni Battista,Department of Genetics
[5] Biology and Biochemistry - University of Torino,undefined
来源：
BMC Immunology | / 11卷
关键词：
Treg Cell; Connective Tissue Growth Factor; Iloprost; Critical Limb Ischemia; Skin Fibrosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Iloprost infusion does not reduce oxidative stress in systemic sclerosis
    Volpe, Alessandro
    Biasi, Domenico
    Caramaschi, Paola
    Bambara, Lisa Maria
    Carletto, Antonio
    Degan, Maurizio
    Minuz, Pietro
    RHEUMATOLOGY INTERNATIONAL, 2008, 28 (04) : 335 - 337
  • [22] EFFICACY OF COMBINATION THERAPY WITH ILOPROST AND BOSENTAN IN THE TREATMENT OF SYSTEMIC SCLEROSIS
    Macri, V.
    Vasile, M.
    Sciarra, I.
    Stefanantoni, K.
    Spadaro, A.
    Ceccarelli, F.
    Riccieri, V.
    Valesini, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S165 - S165
  • [23] The safety of iloprost in systemic sclerosis in a real-life experience
    Bellando-Randone, S.
    Bruni, C.
    Lepri, G.
    Fiori, G.
    Bartoli, F.
    Conforti, M. L.
    Moggi-Pignone, A.
    Guiducci, S.
    Giuggioli, D.
    Colaci, M.
    Spinella, A.
    Ferri, C.
    Matucci-Cerinic, M.
    CLINICAL RHEUMATOLOGY, 2018, 37 (05) : 1249 - 1255
  • [24] Flow mediated dilatation in systemic sclerosis: Effects of iloprost treatment
    Giannattasio, C
    Gentile, G
    Failla, M
    Pozzi, M
    Gardinali, M
    Meles, E
    Zazzeron, C
    Fantini, E
    Maestroni, S
    Mancia, G
    JOURNAL OF HYPERTENSION, 2003, 21 : S160 - S160
  • [25] The safety of iloprost in systemic sclerosis in a real-life experience
    S. Bellando-Randone
    C. Bruni
    G. Lepri
    G. Fiori
    F. Bartoli
    ML Conforti
    A. Moggi-Pignone
    S. Guiducci
    D. Giuggioli
    M. Colaci
    A. Spinella
    C. Ferri
    M. Matucci-Cerinic
    Clinical Rheumatology, 2018, 37 : 1249 - 1255
  • [26] Humoral and cellular immune response to elastin in patients with systemic sclerosis
    Daskalova, M
    Taskov, H
    Dimitrova, E
    Baydanoff, S
    AUTOIMMUNITY, 1997, 25 (04) : 233 - 241
  • [27] Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis
    Erre, G. L.
    Passiu, G.
    REUMATISMO, 2009, 61 (02) : 90 - 97
  • [28] The efficacy and cost effectiveness of ILOPROST in the treatment of systemic sclerosis: A comparative analysis
    Meani, L
    Soldi, A
    Ingegnoli, F
    Zeni, S
    Fantini, F
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 297 - +
  • [29] Long-term effects of cyclic therapy with iloprost in systemic sclerosis
    Scarsi, M.
    Rossi, M.
    Danieli, E.
    Frige, A.
    Grottolo, A.
    Zambruni, A.
    Airo, P.
    REUMATISMO, 2008, 60 (02) : 114 - 119
  • [30] Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis
    Zardi, Enrico Maria
    Picardi, Antonio
    Ambrosino, Giovanni
    Fazio, Vito Michele
    Dobrina, Aldo
    Frego, Mauro
    Afeltra, Antonella
    Lumachi, Franco
    IN VIVO, 2006, 20 (03): : 377 - 380
12345